46 Improving Breast Cancer–Related Lymphedema and Upper Extremity Dysfunction: Why Multidisciplinary Care Matters

Background

Advances in breast cancer detection and systemic therapies have substantially improved survival, shifting emphasis toward survivorship care. Breast cancer–related lymphedema (BCRL) and upper extremity dysfunction remain among the most morbid yet potentially preventable survivorship complications. Despite their prevalence, there is no single standardized diagnostic tool for BCRL and no uniform surgical or radiation strategy routinely employed to mitigate risk (Table). Diagnosis represents only the beginning of a lifelong condition, underscoring the critical importance of prevention. In the United States, approximately 3.8 million breast cancer survivors are living today, with an estimated 20,000 new cases of BCRL diagnosed annually. Risk is multifactorial and influenced by axillary surgical approach, extent of regional nodal irradiation, systemic therapy, and patient-specific factors such as body mass index. These complexities highlight the need for coordinated, multidisciplinary strategies to improve prevention, detection, and management.

Objective/Aim

This review synthesizes current evidence on the prevention, evaluation, and management of breast cancer–related lymphedema in the modern survivorship era. We highlight gaps in standardized assessment, emphasize the importance of multidisciplinary care, and review emerging surgical and radiation strategies designed to minimize BCRL risk.

Materials and Methods

A focused narrative review of the peer-reviewed literature was conducted, including randomized controlled trials, prospective cohort studies, and systematic reviews. Surgical strategies evaluated included axillary reverse mapping, immediate lymphatic reconstruction, prophylactic lymphovenous bypass, and physiologic vs excisional surgical techniques. Evidence related to surgical timing, patient selection, lymphedema incidence, functional outcomes, and quality-of-life measures was synthesized. Studies describing surgical innovations that inform or modify radiation planning to preserve lymphatic reconstructions were specifically included. Findings were organized to identify best practices, limitations of current evidence, and priorities for future investigation.

Results

BCRL incidence varied widely based on axillary treatment intensity, with axillary lymph node dissection emerging as the strongest independent risk factor. Sentinel lymph node biopsy alone was associated with the lowest BCRL rates, whereas combined axillary lymph node dissection and regional nodal irradiation conferred the highest long-term risk. Surgical mitigation strategies, including axillary reverse mapping and immediate lymphatic reconstruction, consistently reduced BCRL incidence compared with conventional axillary dissection and were associated with improved lymphatic function and patient-reported quality of life. Prophylactic lymphovenous bypass further decreased both clinical lymphedema rates and symptom burden in high-risk patients. Bioimpedance spectroscopy–based surveillance enabled earlier detection of subclinical disease and reduced progression to chronic BCRL. Emerging radiation planning approaches that intentionally spare lymphatic reconstructions significantly reduced dose to critical lymphatic structures.

Conclusion

BCRL remains a common and morbid survivorship complication, strongly influenced by axillary surgery and nodal irradiation. Evidence increasingly supports the integration of surgical mitigation strategies, early surveillance, and coordinated radiation planning within multidisciplinary care pathways to reduce BCRL risk and improve long-term outcomes. Standardization of assessment and broader adoption of preventive strategies are needed, and future high-quality trials will be essential to refine patient selection and optimize implementation in routine breast cancer care.